您好!欢迎来到首都医科大学附属北京胸科医院官方网站!

引导页

科室介绍

Department

您所在的位置: 首页 >> 科室介绍 >> 转化研究室>> 著作 >>正文

著作

著作

字号:+-14

  2023年

  (1) Liu B, Liu Z, Lu X, Wu P, Sun Z, Chu H*, Peng H*. Controllable growth of drug-encapsulated metal-organic framework (MOF) on porphyrinic MOF for PDT/chemo-combined therapy. Mater Design. 2023,111861.

  (2) Duan HJ, Chu HQ, Cao TM, Dai GM, Tian N, Sheng G, Sun ZG*. Investigation of the cell composition and gene expression in the delayed-type hypersensitivity tuberculin skin test. Mil Med Res. 2023, 10(1): 14.

  (3) Tian N, Duan H, Cao T, Dai G, Sheng G, Chu H*, Sun Z*. Macrophage-targeted nanoparticles mediate synergistic photodynamic therapy and immunotherapy of tuberculosis. RSC Adv. 2023, 13(3): 1727-1737.

  (4) Ge Q, Ma Y, Zhang L, Ma L, Zhao C, Chen Y, Huang X, Shu W, Chen S, Wang F, Li B, Han X, Shi L, Wang X, Li Y, Yang S, Cao W, Liu Q, Chen L, Wu C, Ouyang B, Wang F, Li P, Wu X, Xi X, Leng X, Zhang H, Li H, Li J, Yang C, Zhang P, Cui H, Liu Y, Kong C, Sun Z*, Du J*, Gao W*. Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in China. Front Public Health. 2023, 11:1039399.

  2022年

  (1) 王文敬, 孙宏, 孙照刚*.结核分枝杆菌DNA介导模式识别受体激活天然免疫机制的研究进展[J].中国防痨杂志, 2023, 45(04): 426-433.

  (2) 盛钢, 褚洪迁, 刘丁一, 孙照刚*. 临床标本中结核分枝杆菌抗原蛋白鉴定的研究进展[J].中国防痨杂志, 2022, 44(12): 1363-1368.

  (3) 孙照刚. 重视结核分枝杆菌抗原检测技术研发[J]. 中国防痨杂志,2022, 44(02): 120-124.

  (4) 戴广明, 王芬, 曹廷明, 褚洪迁, 黄海荣, 孙照刚*. 实时荧光定量PCR检测不同结核标本及其联合玻璃珠磨菌法检测价值的初步研究[J]. 中国防痨杂志,2022, 44(05): 450-454.

  (5) Jia H, Chu H, Dai G, Cao T, Sun Z. Rv1258c acts as a drug efflux pump and growth controlling factor in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2022, 133: 102172.

  (6) Cao T, Dai G, Chu H, Kong C, Duan H, Tian N, Sun Z*. Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients. Hereditas. 2022, 159(1): 5.

  (7) 段惠娟, 孙照刚, 郝卫东, 魏雪涛, 褚洪迁*. 4种化学物质对HaCaT细胞氧化应激相关基因表达的影响[J]. 癌变·畸变·突变, 2022, 34(03): 192-199+205.

  (8) 许伟喆, 王芳, 褚洪迁*. 光激活纳米材料用于肿瘤免疫治疗的研究进展[J]. 癌变·畸变·突变, 2022, 34(06): 471-475.

  (9) 田娜, 褚洪迁, 孙照刚*. 纳米药物递送系统在结核病治疗中的研究进展[J].中国防痨杂志, 2022,44(07):732-737.

  (10) Liu B, Sun L, Lu X, Yang Y, Peng H, Sun Z*, Xu J*, Chu H*. Real-time drug release monitoring from pH-responsive CuS-encapsulated metal-organic frameworks. RSC Adv. 2022, 12(18): 11119-11127.

  (11) Liu B, Liu X, Zhang X, Wu X, Li C, Sun Z*, Chu H*. Facile synthesis of degradable DOX/ICG co‑loaded metal–organic frameworks for targeted drug release and thermoablation. Cancer Nanotechnology. 2022, 13, 18.

  (12) Chu H, Meng X, Liu B, Liu C, Cheng Y, Sun Z*, Wang Y*. Supramolecular-mediated dual-functional DNA nanocomposites for programmable cancer therapy. Biomater Sci. 2022, 10(13): 3569-3574.

  (13) Zhang XX, Lang YF, Li X, Li Z, Xu YQ*, Chu HQ*. The protective effect of puerarin-loaded mesoporous silicon nanoparticles on alcoholic hepatitis through mTOR-mediated autophagy pathway. Biomed Microdevices. 2022, 24(4): 37.

  (14) Kong C, Xu D, Wang Y, Wang B, Wen J, Wang X, Zhan L, Sun Z, Jia X, Li M, Tang S, Hou D*. Amplitude of low-frequency fluctuations in multiple-frequency bands in patients with intracranial tuberculosis: a prospective cross-sectional study. Quant Imaging Med Surg. 2022, 12(8): 4120-4134.

  (15) Wang F, Duan H, Xu W, Sheng G, Sun Z, Chu H*. Light-activated nanomaterials for tumor immunotherapy. Front Chem. 2022, 10:1031811.

  (16) ShengG, Tian N, Duan H, Sun Z*, Chu H*. Advances in therapeutic nanodrug delivery systems for infectious lung diseases: a review. Acta Materia Medica. 2022, 1(3), 343-364.

  2021年

  (1) Chu H, Cao T, Dai G, Liu B, Duan H, Kong C, Tian N, Hou D*, Sun Z*. Recent advances in functionalized upconversion nanoparticles for light-activated tumor therapy. RSC Adv. 2021, 11(56): 35472-35488.

  (2) Jia H, Xu Y, Sun Z*. Analysis on Drug-Resistance-Associated Mutations among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China. Antibiotics (Basel). 2021, 10(11): 1367.

  (3) Chu H, Hu Y, Zhang B, Sun Z*, Zhu B*. DNA Methyltransferase HsdM Induce Drug Resistance on Mycobacterium tuberculosis via Multiple Effects. Antibiotics (Basel). 2021, 10(12):1544.

  (4) Li X, Geng P, Hong X, Sun Z*, Liu G*. Detecting Mycobacterium Tuberculosis using a nitrofuranyl calanolide-trehalose probe based on nitroreductase Rv2466c. Chem Commun (Camb). 2021, 57(97): 13174-13177.

  (5) 徐玉辉, 孙照刚*. 抗结核药用植物的种类特点及其国内外比较. 中华中医药杂志, 2021, 36(3): 1582-1585.

  (6) 段惠娟, 戴广明, 褚洪迁, 杨震, 包城, 何艳萍, 孙照刚*. 北京市部分学校肺结核病患者及其密切接触者筛查分析. 首都医科大学学报, 2021, 42(02): 273-279.

  (7) 段惠娟, 褚洪迁, 孔成成, 戴广明, 曹廷明, 孙照刚*. 11种结核分枝杆菌抗原皮肤试验反应效果评价[J]. 中国防痨杂志, 2021, 43(03): 255-260.

  (8) Ge J, Chu H, Xiao Q, Hao W, Wei X*. BC and 1,4NQ-BC up-regulate the cytokines and enhance IL-33 expression in LPS pretreatment of human bronchial epithelial cells. Environmental Pollution, 2021,273(5396): 116452.

  (9) Mi Y, Zhao J, Chu H, Li Z, Yu M, Li L*. Upconversion luminescence-controlled DNA computation for spatiotemporally resolved, multiplexed molecular imaging. Anal Chem. 2021, 93(4): 2500-2509.

  (10) Xu Y,Liang B, Kong C, Sun Z*. Traditional medicinal plants as a source of anti-tuberculosis drugs-a system review. Biomed Res Int. 2021, 12; 9910365.

  2020年

  (1) Xiao Q, Song Y, Chu H, Tang M, Jiang J, Meng Q, Hao W, Wei X*. 1,4NQ-BC enhances the lung inflammation by mediating the secretion of IL-33 which derived from macrophages. Environ Pollut. 2020, 265(Pt A): 114729.

  (2) 孙照刚, 李自慧, 张洪静, 孙琦, 潘丽萍, 张宗德, 许绍发*. 适用于结核分枝杆菌微测序耐药基因芯片的多重PCR体系的优化与评价. 临床肺科杂志, 2020, 25(2): 163-166.

  (3) Chu H, Tao X, Sun Z, Hao W, Wei X*. Galactooligosaccharides protects against DSS-induced murine colitis through regulating intestinal flora and inhibiting NF-κB pathway. Life Sci. 2020, 242: 117220.

  (4) Xu Y, Tang S, Yang H, Sun Z. Changes of the Anti-tuberculosis formula of herbs during the past three decades in contrast to the ancient ones. Chin J Integr Med. 2020, 27(5): 388-393.

  (5) Liu L, Kong C, Fumagalli M, Savková K, Xu Y, Huszár S, Sammartino JC, Fan D, Chiarelli LR, Mikušová K*, Sun Z*, Qiao C*. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. Eur J Med Chem, 2020, 208: 112773.

  2019年

  (1) Xie Z, Zhou N, Chi Y, Huang G, Wang J, Gao H, Xie N, Ma Q, Yang N, Duan Z, Nie W*, Sun Z*, Chu N*. Nosocomial tuberculosis transmission from 2006 to 2018 in Beijing Chest Hospital, China. Antimicrob Resist Infect Control. 2020, 24;9(1):165.

  (2) 孔成成, 贾红兵, 段惠娟, 梁倩, 马异峰, 尚媛媛, 孙照刚*. 不同性状痰标本的前处理液沉渣对快速培养污染的影响分析. 中国防痨杂志. 2019, 41(4): 378-383.

  (3) 孙照刚, 张洪静, 李自慧, 孙琦, 吕琳娜, 潘丽萍, Sandy Gilbert, 张宗德, 许绍发*. James Xia. 新一代微测序基因芯片的设计及其耐药检测效果的初步研究.中国防痨杂志,2019, 41(6):598-604.

  (4) Chu H, Zhao J, Mi Y, Di Z, Li L*. NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices. Nat Commun. 2019, 10(1):2839.

  (5) Chu H, Zhao J, Mi Y, Zhao Y, Li L*. Near-infrared light-initiated hybridization chain reaction for spatially and temporally resolved signal amplification. Angew Chem Int Ed Engl. 2019, 58(42):14877-14881.

  (6) Mu R, Kong C, Yu W, Wang H, Ma Y, Li X, Wu J, Somersan-Karakaya S, Li H, Sun Z*, Liu G*. Nitrooxidoreductase Rv2466c-Dependent Fluorescent Probe for Mycobacterium tuberculosis Diagnosis and Drug Susceptibility Testing. ACS Infect Dis. 2019, 5(6):949-961.

  (7) Hu Y, Feng Y, Wu J, Liu F, Zhang Z,Hao Y, Liang S, Li B, Li J, Lv N, Xu Y*, Zhu B*, Sun Z*. The gut microbiome signatures discriminateHealthy from pulmonary tuberculosis patients. Front. Cell. Infect. Microbiol. 2019, 9(4):90.

  (8) Chen S, Dai G, Dong L, Li YX, Huo F, Shang Y, Huang H*. Determination of the critical concentration of rifabutin for susceptibility testing using the proportion method with löwenstein-jensen medium against mycobacterium tuberculosis isolates. Lab Med. 2019, 50(3):292-297.

  (9) Cao D, Zhang Z, Yang Z, Ma S, Sun Z, Duan H, Zhu B, Zhao F*. The association between tuberculin skin test result and active tuberculosis risk of college students in Beijing, China: a retrospective cohort study. BMC Infect Dis. 2019, 19(1):619.

  2018年

  (1) 武剑楠, 孔成成, 霍凤敏, 孙照刚*. CDG-3荧光探针检测结核分枝杆菌的初步研究. 中国防痨杂志. 2018, 40(4): 378-383.

  (2) Wu J, Kong C, Huo F, Liang Q, Ma Y, Shang Y, Zhao L, Sun Z*. Mono-Prep System increases the case-finding of sputum smear microscopy for diagnosing tuberculosis. J Intl Med Res. 2018, 46(12):5137-5142.

  (3) Cheng Y, J. Xie, K.-H. Lee, R. L. Gaur, A. Song, T. Dai, H. Ren, J. Wu, Z. Sun, N. Banaei,D. Akin, J. Rao, Rapid and specific labeling of single live Mycobacterium tuberculosis with a dual-targeting fluorogenic probe. Sci. Transl. Med. 2018, 10(454): eaar4470.

  (4) Xu Y, Liu F, Chen C, Wu J, Hu Y, Zhu B, Sun Z*. In vivo evolution of drug-resistant Mycobacterium tuberculosis in patients during long-term treatment. BMC Gnomics. 2018, 19(1):640.